Heart drugs tested to shield breast cancer patients from treatment side effects
NCT ID NCT06844669
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 33 times
Summary
This study tested whether giving heart medications (carvedilol and empagliflozin) before or alongside HER2-targeted therapy could prevent heart damage in people with HER2-positive breast cancer. The trial aimed to see if it was possible to enroll enough patients and if the drugs were safe and tolerable. Only 7 participants were enrolled before the study was ended early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.